Equity Research, Broker Reports, and media content on VISTIN PHARMA AS

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about VISTIN PHARMA AS
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard
Login

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on VISTIN PHARMA AS. We currently have 0 research reports from 0 professional analysts.

Open
0.00
Volume
0.0m
Range
0.00/0.00
Market Cap
0m
52 Week
0.00/0.00

Latest News/RNS

(more news)
Date Source Announcement
11Jul17 11:04 GNW Vistin Pharma ASA : Vistin Pharma announces the sale of its Opioids and CMO business
28Feb17 06:00 GNW Vistin Pharma ASA : Fourth quarter and preliminary 2016 results
31Oct16 06:01 GNW Vistin Pharma ASA third quarter 2016: Investing in future growth
30Aug16 06:31 GNW Vistin Pharma ASA : Vistin Pharma to double its metformin production capacity by 2019 with MNOK 120 investment
30Aug16 06:30 GNW Vistin Pharma ASA : Solid second quarter driven by all-time high metformin revenue
28Apr16 06:00 GNW Vistin Pharma ASA : Strong first quarter 2016 and bright outlook
23Feb16 06:00 GNW Vistin Pharma ASA : Solid fourth quarter results and positive market outlook
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    VISTIN PHARMA AS

  • Providers covering

    VISTIN PHARMA AS

  • 22 Aug 17

Morning Note

OptiBiotix* (OPTI): LP-LDL agreement for US and ROW (CORP) | Proactis* (PHD): Strong trading update (CORP)

Companies: Optibiotix Health Proactis

  • 17 Aug 17

Small Cap Breakfast

Avingtrans (AVG.L) Sch1 on its Reverse Takeover of Hayward Tyler (HAYT). Combined market cap of c.£75m. Expected 01 September 2017 OnTheMarket—Intention to float on AIM to raise c. £50m which will be used to fund the growth of the OnTheMarket.com portal, already the third biggest UK residential property portal provider. Expected valuation £200m to £250m. Kosmos Energy—. Secondary listing, currently on NYSE. Oil and gas exploration and production company focused on frontier and emerging areas along the Atlantic Margins. During the first half of 2017, gross sales volumes from Ghana averaged approximately 132,000 barrels of oil per day (net: 26,900 bopd). Due 21 August. No offer. NYSE:KOS. Mkt Cap £2.54bn. Myanmar Strategic Holdings—Intention to float from the independent developer and operator of consumer-focused businesses in Myanmar, one of the fastest growing economies in the world. Expected Mkt Cap $22.7m at $10 per share. No details on funds to be raised. Expected late August. Hipgnosis Songs Fund investment Company offering pure-play exposure to Songs and associated musical intellectual property rights. Offer raising £200m at 100p. The Company has decided to extend the closing date for the Placing, Offer for Subscription and Intermediaries Offer to 1 August 2017. The Company may bring forward this closing date at any time. Admission 15 September 2017

Companies: VOF SRT MED WLF KMK YOLO OXB CLIN IDOX VOG

  • 17 Aug 17

N+1 Singer - Oxford BioMedica - Interim results; CTL019 approval anticipated by early October

Oxford BioMedica’s interim results highlight the continued step up in bioprocessing and commercial development income. A new agreement with Novartis for the commercial and clinical supply of lentiviral vectors was recently established following the FDA advisory committee unanimously recommending CTL019 for approval in acute lymphoblastic leukaemia (ALL). Approval is anticipated by early October 2017. Novartis also announced encouraging Phase II results in a trial evaluating CTL019 in diffuse large B-cell lymphoma (DLBCL) in June with full data and potential filing in Q4. Oxford BioMedica is eligible to a royalty on sales in both indications. We look forward to regulatory approval of CTL019 in ALL in the coming months.

Companies: Oxford Biomedica
  • 21 Aug 17

N+1 Singer - Morning Song 21-08-2017

ECO Animal Health Group (EAH LN) Marketing authorisation for Aivlosin® in Egypt | Halfords Group (HFD LN) Positive view on stock re-iterated ahead of update | Rathbone Brothers (RAT LN) Potential merger with Smith and Williamson | Tribal Group (TRB LN) 2 Contracts won, total value £25.3m

Companies: HFD TRB EAH RAT

  • 15 Aug 17

Inspiring …

Vectura has a strong and growing revenue stream that generates sufficient cash flow to support a broad development pipeline founded on an extensive base of IP. In our view, share price significantly undervalues the company, currently attributing value to only the marketed products and cash – with the whole of the very extensive development portfolio, both partnered and in house, as upside. We believe the recent weakness in the shares, which have not recovered from the delay in VR315 approval, offers a very attractive entry point for investors. We initiate coverage with a BUY and a 150p target price.

Companies: Vectura Group
  • 16 Aug 17

AIM Breakfast

LoopUp—The provider of conference calls and online meetings is seeking to join AIM. 2015 revs of £9.2m and EBITDA of £1.02m | Bacanora Lithium— To list on AIM around 28 Sep as holding company for TSX listed Bacanora Minerals at £100m market cap | Aura Energy—ASX listed uranium developer (ASX:AEE) expected to join AIM 6 September | Autins Group plc - The acoustic and thermal insulation specialist now looks to join AIM late August

Companies: PEG COG IKA OMI EZH MMH UBI CIRC EPO

  • 09 Aug 17

Sector Consolidation Continues

Last week saw the acquisition of Aptuit by Evotec (EVT.DE) for $300m. This is against forecasted revenues 2017 of €100m to €110m a multiple of circa 2.4x (forward) and adjusted EBITDA in 2016 of €11m, a multiple of circa 23x (historical).

Companies: Venn Life Sciences
  • 21 Aug 17

Small Cap Breakfast

Kosmos Energy (KOS.L)—Secondary listing (Standard), currently on NYSE. Oil and gas exploration and production company focused on frontier and emerging areas along the Atlantic Margins. During the first half of 2017, gross sales volumes from Ghana averaged approximately 132,000 barrels of oil per day (net: 26,900 bopd). No offer. NYSE:KOS. Mkt Cap £2.54bn. | Pembridge Resources (PERE.L) - the natural resource exploration and development company has today moved from AIM to the Standard List of the Main Market.

Companies: PHE EAH SPSY FDEV SSY MERC AVN MUBL ITM DCTA

  • 17 Aug 17

N+1 Singer - Morning Song 17-08-2017

IDOX (IDOX LN) Attractive £5.0m acquisition in Public Sector, strengthens position further | Oxford BioMedica (OXB LN) Interim results; CTL019 approval anticipated by early October | ReNeuron Group (RENE LN) Pipeline continues to progress

Companies: OXB IDOX RENE

  • 31 Jul 17

N+1 Singer - Morning Song 31-07-2017

Alliance Pharma (APH LN) Diclectin® non-approval in the UK | Bodycote (BOY LN) Good momentum; PBT forecasts increased | CVS Group (CVSG LN) Positive YE update & 7-8% EPS upgrades for FY18/19 | GlobalData (DATA LN) Revenues ahead | Ground Rents Income Fund (GRIO LN) Prudent and proactive approach to ten year doubling assets | IQE (IQE LN) VCSEL ramp up just the start | Senior (SNR LN) Solid interims; Outlook positive | StatPro Group (SOG LN) Contract extension | Tribal Group (TRB LN) Continued positive progress

Companies: IQE BOY DATA CVSG SNR GRIO TRB SOG APH

  • 17 Jul 17

Morning Note

OptiBiotix* (OPTI): LP-LDL supply agreement for NZ / Australia (CORP) | Elecosoft* (ELCO): H1 in line with expectations (CORP)

Companies: Optibiotix Health Elecosoft

  • 14 Aug 17

Small Cap Breakfast

OnTheMarket—Intention to float on AIM to raise c. £50m which will be used to fund the growth of the OnTheMarket.com portal, already the third biggest UK residential property portal provider. Expected valuation £200m to £250m. Wilmcote Holdings plc—Sch1 from the Company established with the objective of creating value for its investors through the acquisition and subsequent development of target businesses in the downstream and specialty chemicals sector. Offer raising £15m at 120p with market cap of £25m. Expected 17 August 2017 Hipgnosis Songs Fund investment Company offering pure-play exposure to Songs and associated musical intellectual property rights. Offer raising £200m at 100p. The Company has decided to extend the closing date for the Placing, Offer for Subscription and Intermediaries Offer to 1 August 2017. The Company may bring forward this closing date at any time. Admission 15 September 2017

Companies: DCD EAH GGP GTC FISH AAZ WJG SAV FTC LWRF

  • 18 Aug 17

Another beat, navigated by mature drugs and R&D caps

Lundbeck reported strong Q2 17 results, ahead of consensus as well as our estimates (significant beat on profitability). Revenue increased 14% yoy to DKK4.3bn (+15% at LC), driven by the continued robust performance of the core portfolio (all at LC) – Brintellix /Trintellix (+70%), Rexulti (+56%), Northera (+48%), Onfi (+27%) and Abilify Maintena (+25%). The key differentiator, however, was the solid growth posted by the off-patent drug Sabril (+22%, lost patent in 2016) due to delayed launch of its generic, approved in April 2017 (by Par Pharma, subsidiary of Endo Pharma). On the other hand, while Xenazine (-28% at LC, albeit better than market expectations) continued to suffer from its patent expiration, revenue from other pharmaceuticals declined by 6% due to generic competition on Azilect (recently approved in China for Parkinson’s) and Ebixa in Europe. Revenue from contract manufacturing declined by 45% to DKK136m. Core EBIT increased 77% to DKK1.3bn (margin: 30%, 19.4% in Q2 16), driven by the strong operating leverage from the North American operations and cost control initiatives (primarily R&D). Despite higher financial expenses (primarily due to currency fluctuations), a 12.4% yoy reduction in the effective tax rate took earnings up c.162% to DKK608m (margin up c.800bp to 14%). Geographically, while the US remained the primary facilitator (+21% LC growth), Europe posted a marginal turnaround after a prolonged period in the red (+4% LC in Q2 17; -6% in Q1 17 and -25% in FY 16, due to patent expiries of the legacy portfolio) driven by Abilify Maintena and Brintellix (both have now been launched in most major European markets). International markets too picked up pace, recording a c.17% LC growth in the quarter (+3% in Q1), driven by the strong uptake of Brintellix (launch in 20 countries in the region) and the robust performance of Abilify Maintena in Australia (the only international market for the drug to date), offset to an extent by lower sales of Cipralex and Azilect. Factoring in the encouraging Q2 results, management has upgraded its FY 17 outlook (for the second successive quarter this year and the fifth quarter in a row) – revenue to reach DKK16.7-17.5bn (from the earlier DKK16.5-17.3bn) and EBIT guidance to DKK4.1-4.5bn (from the previous DKK3.6-4.0bn, including DKK200m from the divestiture of properties in May 2017).

Companies: H. Lundbeck
  • 03 May 17

FY17 Results – a year of change

Quantum Pharma plc, the service-led niche pharmaceutical developer and supplier to the health and care sectors, has reported its Preliminary financial results for the 12 months to January 31, 2017. Net sales grew by 28% to £88.8m while adjusted EBITDA was in-line with expectations at £10.1m, down from £12.5m in FY16. During the year management took a number of decisive actions to focus and simplify the business, and the company is now on a much stronger operational and financial footing as it moves forward. The actions resulted in the prioritisation of the product development portfolio within the Niche Division and the closure of the loss-making NuPharm. The core Specials division continues to generate the majority of Group adjusted EBITDA and its strength in the UK unlicensed market was underscored again by renewed exclusive supply contracts with 3 of the 4 main wholesale and pharmacy chains. Our profit forecasts for FY2018 and FY2019 remain unchanged. Quantum is valued at around a 40% discount to peers at 7.4x EV/EBITDA (9.8x PE) in the year to Jan 31st, 2018.

Companies: Quantum Pharma
  • 21 Aug 17

N+1 Singer - ECO Animal Health Group - Marketing authorisation for Aivlosin® in Egypt

ECO Animal Health has received its fifth Aivlosin® marketing authorisation of the year with the most recent being in Egypt in chickens laying eggs for human consumptions in a water soluble formulation. Egypt is the second most important egg producing country in the Middle East and just outside the top twenty globally. ECO Animal Health continues its global roll out of Aivlosin® for commercial layers after it was first approved in a water soluble formulation for the treatment of layers in Europe in 2016. We re-iterate our positive stance and continue to expect Aivlosin® to generate strong growth in multiple geographies.

Companies: Eco Animal Health Group